Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Fourth Quarter Earnings
April 07 2008 - 1:33PM
PR Newswire (US)
NEW YORK, April 7, 2008 /PRNewswire-FirstCall/ -- Forest
Laboratories, Inc. (NYSE:FRX), an international manufacturer and
marketer of pharmaceutical products, will release its Fiscal 2008
Fourth Quarter financial results before the U.S. stock market opens
on Tuesday, April 15, 2008. Later that day, at 10:00 AM EDT, Forest
will host a conference call where Dr. Lawrence Olanoff, President
and Chief Operating Officer and Frank Perier, Senior Vice President
and Chief Financial Officer, will discuss the financial results and
relevant company and industry topics. The conference call will be
webcast live beginning at 10:00 AM EDT on the Company's website
http://www.frx.com/ and also on the website
http://www.streetevents.com/. Please log on to either website at
least fifteen minutes prior to the conference call as it may be
necessary to download software to access the call. A replay of the
conference call will be available until April 30, 2008 at both
websites and also by dialing 1-800-642-1687 (US investors) or
+1-706-645-9291 (international investors), ID 42636974. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) About
Forest Laboratories and Its Products Forest Laboratories is a
US-based pharmaceutical company dedicated to identifying,
developing, and delivering products that make a positive difference
in peoples' lives. Forest Laboratories' growing product line
includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for
adults for the initial and maintenance treatment of major
depressive disorder and generalized anxiety disorder; Namenda(R)
(memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist
indicated for the treatment of moderate to severe Alzheimer's
disease; Campral(R)* (acamprosate calcium), indicated in
combination with psychosocial support for the maintenance of
abstinence from alcohol in patients with alcohol dependence who are
abstinent at treatment initiation, and Bystolic(TM) (nebivolol), a
beta-adrenergic receptor blocking agent indicated for the treatment
of hypertension. In addition to our growing product line, Forest
also co-promotes the Daiichi Sankyo, Inc. product Azor(TM)*
(amlodipine and olmesartan medoxomil), a calcium channel blocker
and angiotensin receptor blocker combination product indicated for
the treatment of hypertension. For more information, visit
http://www.frx.com/. * Azor is a trademark of Daiichi Sankyo, Inc.
and Campral is a registered trademark of Merck Sante s.a.s., a
subsidiary of Merck KGaA, Darmstadt, Germany. Except for the
historical information contained herein, this release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve
a number of risks and uncertainties, including the difficulty of
predicting FDA approvals, the acceptance and demand for new
pharmaceutical products, the impact of competitive products and
pricing, the timely development and launch of new products, and the
risk factors listed from time to time in the Forest Laboratories'
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any
subsequent SEC filings.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE:
Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice
President - Investor Relations of Forest Laboratories, Inc.,
+1-212-224-6714, Web site: http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024